Skip to main content

Advertisement

SpringerLink
Log in

GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Hamadani M, Craig M, Awan FT, Devine SM . How we approach patient evaluation for hematopoietic stem cell transplantation. Bone Marrow Transplant 2010; 45: 1259–1268.

    Article  CAS  Google Scholar 

  2. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  Google Scholar 

  3. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961–968.

    Article  CAS  Google Scholar 

  4. Extermann M . Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35: 181–200.

    Article  CAS  Google Scholar 

  5. Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M . Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission-a review from the Acute Leukemia Working Party of the EBMT. Haematologica 2015; 100: 859–869.

    Article  Google Scholar 

  6. Russell NH, Kjeldsen L, Craddock C, Pagliuca A, Yin JA, Clark RE et al. A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. Leukemia 2015; 29: 1478–1484.

    Article  CAS  Google Scholar 

  7. Platzbecker U . Who benefits from allogeneic transplantation for myelodysplastic syndromes?: new insights. Hematology Am Soc Hematol Educ Program 2013; 2013: 522–528.

    Article  Google Scholar 

  8. Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood 2015; 125: 1333–1338.

    Article  CAS  Google Scholar 

  9. Bolanos-Meade JKJ, Reshef R . A Multicenter Phase II Trial Randomizing Novel Approaches for Graft-versus-host Disease Prevention Compared to Contemporary Controls (1203). Available at https://clinicaltrials.gov/ct2/show/NCT02208037. Accessed on 19 January 2015.

  10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, Blood and Marrow Transplant Program, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA

    A Nazha, L Rybicki, D Abounader, B Bolwell, R Dean, A T Gerds, D Jagadeesh, B K Hamilton, B T Hill, M Kalaycio, H Liu, B Pohlman, R Sobecks, M A Sekeres & N S Majhail

Authors
  1. A Nazha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Abounader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A T Gerds
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Jagadeesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B K Hamilton
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. B T Hill
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. H Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M A Sekeres
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. N S Majhail
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Nazha.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nazha, A., Rybicki, L., Abounader, D. et al. GvHD-free, relapse-free survival after reduced-intensity allogeneic hematopoietic cell transplantation in older patients with myeloid malignancies. Bone Marrow Transplant 51, 1642–1643 (2016). https://doi.org/10.1038/bmt.2016.254

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.254

  • Springer Nature Limited

Search

Navigation